NeoGenomics Inc NG9
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €14.05
- Day Range
- €14.10–14.10
- 52-Week Range
- —–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 128.48M
- Market Cap
- €1.81B
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 109.65
- Price/Sales
- 2.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 1.09%
Company Profile
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,500
- Website
- https://www.neogenomics.com
Valuation
|
Metric
|
NG9
|
|---|---|
Price/Earnings (Normalized) | 109.65 |
Price/Book Value | 2.62 |
Price/Sales | 2.77 |
Price/Cash Flow | 38.69 |
Price/Earnings
NG9
Financial Strength
|
Metric
|
NG9
|
|---|---|
Quick Ratio | 3.03 |
Current Ratio | 3.60 |
Interest Coverage | −22.29 |
Quick Ratio
NG9
Profitability
|
Metric
|
NG9
|
|---|---|
Return on Assets (Normalized) | 1.45% |
Return on Equity (Normalized) | 2.39% |
Return on Invested Capital (Normalized) | 1.36% |
Return on Assets
NG9
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|dn<BP>wb | LOCK|g# | $243B | |||
| Danaher Corp
DHR
| LOCK|f^l^K$W | LOCK|>#Q | $155B | |||
| Agilent Technologies Inc
A
| LOCK|<<Ds>>zq | LOCK|rl! | $48B | |||
| IQVIA Holdings Inc
IQV
| LOCK|$h#qZf> | LOCK|$&&B< | $43B | |||
| Waters Corp
WAT
| LOCK|L$S?^jh | LOCK|ps | $43B | |||
| Illumina Inc
ILMN
| LOCK|xm&QX? | LOCK|S&vl | $42B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|Ws@$>c#X | LOCK|nN< | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|p^mL&j^ | LOCK|S<$#! | $31B | |||
| Quest Diagnostics Inc
DGX
| LOCK|gvt$#d | LOCK|?c<^# | $25B | |||
| Labcorp Holdings Inc
LH
| LOCK|q>m^P!vP | LOCK|%MNs@ | $25B |
United States